Marinus Pharmaceuticals (NASDAQ:MRNS) Earns Sell Rating from Analysts at StockNews.com

StockNews.com began coverage on shares of Marinus Pharmaceuticals (NASDAQ:MRNS) in a report issued on Sunday morning. The firm issued a sell rating on the biopharmaceutical company’s stock.

A number of other brokerages have also issued reports on MRNS. EF Hutton Acquisition Co. I upgraded Marinus Pharmaceuticals to a “strong-buy” rating in a research report on Monday, September 30th. TD Cowen reiterated a “hold” rating on shares of Marinus Pharmaceuticals in a research report on Friday, October 25th. Jefferies Financial Group restated a “hold” rating and set a $0.50 price target (down from $5.00) on shares of Marinus Pharmaceuticals in a research report on Friday, October 25th. JMP Securities reissued a “market perform” rating on shares of Marinus Pharmaceuticals in a research note on Thursday, October 24th. Finally, Oppenheimer upgraded shares of Marinus Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $6.00 target price on the stock in a report on Monday, September 23rd. One research analyst has rated the stock with a sell rating, eight have issued a hold rating, two have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $4.79.

Marinus Pharmaceuticals Stock Down 0.1 %

Shares of MRNS stock opened at $0.53 on Friday. The business has a 50 day moving average of $0.33 and a two-hundred day moving average of $1.03. The company has a market cap of $29.43 million, a P/E ratio of -0.22 and a beta of 1.03. Marinus Pharmaceuticals has a 52 week low of $0.22 and a 52 week high of $11.26.

Hedge Funds Weigh In On Marinus Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Renaissance Technologies LLC acquired a new position in Marinus Pharmaceuticals in the second quarter worth about $727,000. Acadian Asset Management LLC bought a new stake in shares of Marinus Pharmaceuticals during the second quarter worth approximately $813,000. Squarepoint Ops LLC bought a new stake in shares of Marinus Pharmaceuticals during the 2nd quarter valued at $206,000. AQR Capital Management LLC lifted its stake in Marinus Pharmaceuticals by 70.3% in the second quarter. AQR Capital Management LLC now owns 31,333 shares of the biopharmaceutical company’s stock valued at $37,000 after buying an additional 12,934 shares during the period. Finally, Point72 DIFC Ltd acquired a new stake in shares of Marinus Pharmaceuticals in the 2nd quarter valued at approximately $28,000. 98.80% of the stock is currently owned by institutional investors.

About Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.